ChemSpider 2D Image | VASOTEC | C18H28N2O7

VASOTEC

  • Molecular FormulaC18H28N2O7
  • Average mass384.424 Da
  • Monoisotopic mass384.189636 Da
  • ChemSpider ID5292946
  • defined stereocentres - 3 of 3 defined stereocentres


More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

(2S)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid
278-459-3 [EINECS]
76420-72-9 [RN]
Enalaprilat [USP] [Wiki]
Enalaprilat (hydrate)
Enalaprilat dihydrate
L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-, hydrate (1:2) [ACD/Index Name]
MFCD00941393
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-prolindihydrat [German] [ACD/IUPAC Name]
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline dihydrate [ACD/IUPAC Name]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

GV0O7ES0R3 [DBID]
MK 422 [DBID]
D03769 [DBID]
MK-422 [DBID]
UNII:GV0O7ES0R3 [DBID]
UNII-GV0O7ES0R3 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Chemical Class:

      The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for r eduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprila t is not absorbed by mouth but is administered by intravenous injection. ChEBI https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59877, CHEBI:59877
    • Bio Activity:

      Angiotensin-converting Enzyme (ACE) MedChem Express HY-B0231
      Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM. MedChem Express
      Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.; Target: ACE; Enalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. MedChem Express HY-B0231
      Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.;Target: ACEEnalaprilat has high affinity for human endothelial ACE with IC50 of 1.94 nM in vitro binding assay by displacing a saturating concentration of [125I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments [1]. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC50 of 90 mM [2].Administration of Enalaprilat induces a significant reduction of MAP at 70 minutes compared with the placebo group during haemorrhagic shock in rats, and results in a 50% reduction of CO, a general tendency of EB extravasation which is significant in the kidney and lungs, and a significant increase in ileal EB extravasation (53%) [3]. MedChem Express HY-B0231
      Metabolism/Protease MedChem Express HY-B0231
      Metabolism/Protease; MedChem Express HY-B0231

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site






Advertisement